The cost effectiveness of B-Type natriuretic peptide measurement in the primary care setting-a UK perspective

Congest Heart Fail. 2006 Mar-Apr;12(2):103-7. doi: 10.1111/j.1527-5299.2006.04885.x.
No abstract available

MeSH terms

  • Algorithms
  • Biomarkers / blood
  • Cost-Benefit Analysis
  • Disease Progression
  • Dyspnea / diagnosis
  • Heart Failure / diagnosis*
  • Heart Failure / physiopathology
  • Humans
  • Mass Screening / economics*
  • Mass Screening / methods
  • Models, Econometric
  • Natriuretic Peptide, Brain / blood*
  • Primary Health Care / economics*
  • Primary Health Care / methods
  • Prognosis
  • United Kingdom

Substances

  • Biomarkers
  • Natriuretic Peptide, Brain